Cargando…
Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
Tildrakizumab is a high‐affinity, humanized immunoglobulin G1κ, anti‐interleukin‐23p19 monoclonal antibody recently approved in Japan for treatment of plaque psoriasis. We report results from Japanese patients treated with tildrakizumab in the multinational, randomized, double‐blind, placebo‐control...
Autores principales: | Igarashi, Atsuyuki, Nakagawa, Hidemi, Morita, Akimichi, Okubo, Yukari, Sano, Shigetoshi, Imafuku, Shinichi, Tada, Yayoi, Honma, Masaru, Mendelsohn, Alan M., Kawamura, Masaki, Ohtsuki, Mamitaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247960/ https://www.ncbi.nlm.nih.gov/pubmed/33630387 http://dx.doi.org/10.1111/1346-8138.15789 |
Ejemplares similares
-
Long‐term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5‐year extension of a phase 3 study (reSURFACE 1)
por: Imafuku, Shinichi, et al.
Publicado: (2021) -
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
por: Asahina, Akihiko, et al.
Publicado: (2023) -
Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch
por: Ohtsuki, Mamitaro, et al.
Publicado: (2017) -
Long‐term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3‐year results of a double‐blind extension study
por: Okubo, Yukari, et al.
Publicado: (2019) -
Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
por: Umezawa, Yoshinori, et al.
Publicado: (2021)